Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1996-3-27
|
| pubmed:abstractText |
Fotemustine and dacarbazine constitute the most active single chemotherapeutic agents in the treatment of melanoma. In this phase II study we evaluated the activity and toxicity of a combination of fotemustine, dacarbazine and vindesine as a means of increasing response rate and survival time. Between September 1989 and November 1993, 43 patients with advanced melanoma were treated with a combination of 100 mg/m2 fotemustine on days 1 and 8, 250 mg/m2 dacarbazine on days 15 and 16 and 2 mg/m2 vindesine on days 15 and 16 as induction treatment. After a 5-week rest period, the patients exhibiting a response or stable disease received the same drugs administered once every 28 days as maintenance therapy until either progression or toxicity was observed. Among 41 evaluable patients, there were six complete responses and eight partial responses. The overall response rate was 32% (95% confidence interval: 18-46%), with 8 months median duration of response. Median survival time was 10 months. This regimen was well tolerated. From this large phase II study, we conclude that such a combination is active against advanced malignant melanoma and seems to be more effective than fotemustine or dacarbazine used alone, especially on visceral metastatic sites.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Dacarbazine,
http://linkedlifedata.com/resource/pubmed/chemical/Nitrosourea Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Organophosphorus Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Vindesine,
http://linkedlifedata.com/resource/pubmed/chemical/fotemustine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0960-8931
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
5
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
419-24
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8589616-Adult,
pubmed-meshheading:8589616-Aged,
pubmed-meshheading:8589616-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8589616-Bone Marrow Diseases,
pubmed-meshheading:8589616-Combined Modality Therapy,
pubmed-meshheading:8589616-Dacarbazine,
pubmed-meshheading:8589616-Disease-Free Survival,
pubmed-meshheading:8589616-Female,
pubmed-meshheading:8589616-Follow-Up Studies,
pubmed-meshheading:8589616-Humans,
pubmed-meshheading:8589616-Male,
pubmed-meshheading:8589616-Melanoma,
pubmed-meshheading:8589616-Middle Aged,
pubmed-meshheading:8589616-Neoplasm Metastasis,
pubmed-meshheading:8589616-Nitrosourea Compounds,
pubmed-meshheading:8589616-Organophosphorus Compounds,
pubmed-meshheading:8589616-Remission Induction,
pubmed-meshheading:8589616-Risk,
pubmed-meshheading:8589616-Salvage Therapy,
pubmed-meshheading:8589616-Survival Rate,
pubmed-meshheading:8589616-Treatment Outcome,
pubmed-meshheading:8589616-Vindesine
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
|
| pubmed:affiliation |
SOMPS, Hopital de la Salpétriere, Paris, France.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|